Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?

Isabelle Ray-Coquard • 23 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer Olaparib
POLO

Isabelle Ray-Coquard, MD, PhD, Léon Bérard Center, Lyon, France, discusses the significance of PARP inhibitors in first-line patients, a controversial topic discussed during the European Society of Gynaecological Oncology (ESGO). Prof. Ray-Coquard highlights the findings of a subgroup analysis of the POLO-1 study (NCT02184195), which evaluated the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Isabelle Ray-Coquard

Personalized medicine for patients with gynecological sarcoma
0:38
Personalized medicine for patients with gynecological sarcoma
Isabelle Ray-Coquard • 23 Oct 2021
PARP inhibitor rechallenging in ovarian cancer
0:46
PARP inhibitor rechallenging in ovarian cancer
Isabelle Ray-Coquard • 23 Oct 2021
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
1:16
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
Isabelle Ray-Coquard • 1 Sep 2021
Testing HRD in the clinic
1:19
Testing HRD in the clinic
Isabelle Ray-Coquard • 1 Sep 2021

Related Videos

The future of antibody-drug conjugates in endometrial cancer
1:10
The future of antibody-drug conjugates in endometrial cancer
Linda Mileshkin • 30 May 2026
B7-H4-directed ADC in endometrial versus ovarian cancer
0:43
B7-H4-directed ADC in endometrial versus ovarian cancer
Linda Mileshkin • 30 May 2026
Barriers to cervical cancer screening among rural women in India
0:54
Barriers to cervical cancer screening among rural women in India
Shailendra Dandge • 31 May 2026
A community-based model for cervical cancer screening uptake in rural India
8:39
A community-based model for cervical cancer screening uptake in rural India
Shailendra Dandge • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals